7Baggers
 Intensity Therapeutics Reports Q3 2025 Financial Results  TipRanks Tue, 11 Nov 2025 04:35:56 GMT
 Intensity Therapeutics Shrinks Losses As Cash Runway Extends  Finimize Fri, 07 Nov 2025 07:40:55 GMT
 Intensity Therapeutics Q3 net loss narrows to $2.7 mln  MarketScreener Thu, 06 Nov 2025 08:00:00 GMT
 Intensity Therapeutics Enters Securities Purchase Agreement  The Globe and Mail Sat, 01 Nov 2025 07:00:00 GMT
 intensity therapeutics stock price, quotes and forecasts  Benzinga Fri, 31 Oct 2025 23:59:00 GMT
 Shelton biotech to raise $4M for novel cancer therapy  Hartford Business Journal Fri, 31 Oct 2025 14:20:22 GMT
 Unexpected Surge: Analyzing INTS Performance  timothysykes.com Fri, 31 Oct 2025 14:18:00 GMT
 Intensity Therapeutics stock up nearly 400% on solid tumour data  Clinical Trials Arena Fri, 31 Oct 2025 07:00:00 GMT
 INTS Stock Price and Chart — NASDAQ:INTS  TradingView Fri, 31 Oct 2025 07:00:00 GMT
 Trending tickers: Apple, Amazon, Netflix, Reddit and Intensity Therapeutics  Yahoo Finance UK Fri, 31 Oct 2025 07:00:00 GMT
 Intensity Therapeutics prices $4 million registered direct offering  Investing.com Fri, 31 Oct 2025 07:00:00 GMT
 Intensity Therapeutics Enters Securities Purchase Agreement  TipRanks Fri, 31 Oct 2025 07:00:00 GMT
 intensity therapeutics shares soar on promising cancer trial results  El-Balad.com Thu, 30 Oct 2025 17:44:35 GMT
 intensity therapeutics shares skyrocket after strong cancer drug trial results  businessupturn.com Thu, 30 Oct 2025 16:06:41 GMT
 Why Is Intensity Therapeutics Stock (INTS) Up 195% Today?  TipRanks Thu, 30 Oct 2025 07:00:00 GMT
 Intensity Therapeutics stock soars after phase 1/2 data publication  Investing.com Thu, 30 Oct 2025 07:00:00 GMT
 Why Is Retail Going Gaga Over INTS Stocks Today?  Stocktwits Thu, 30 Oct 2025 07:00:00 GMT

Intensity Therapeutics
(NASDAQ:INTS) 

INTS stock logo

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon,...

Founded: 2012
Sector: TECHNOLOGY
Industry: GENERAL

Share this website to your friends